ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

70 posts / 0 new
Letzter Beitrag
Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

...wenn nur eines dieser Medikamente den Markt erreicht steht IMNR im

2-stelligen US$ Bereich, Explosionne Biggrin

=> Zur Zeit steht der Kurs bei 0.024 US$!!! :roll:

Eine Möglichkeit Millionär zu werden, Geduld bringt Kohle...100K posten und liegen lassen, das reicht.... Smile

http://www.imnr.com/pipeline/pipeline.htm

http://yahoo.reuters.com/stocks/CompanyProfile.aspx?Type=Full&symbol=IMN...

pays.
Bild des Benutzers pays.
Offline
Zuletzt online: 26.09.2013
Mitglied seit: 19.05.2006
Kommentare: 37
IMNR

Die Frage ist nur: Warum steht die Aktie immernoch bei 0,024$.

Sollte doch eigentlich schon lange knallen :?: - Oder wurden da noch mehr Aktien auf den Markt geschmissen :?:

Gleichwertige Firmen (die das Potenzial wohl ausschöpfen konnten) stehen ja beim 100fachen.

Grüsse pays

Gruss pays

dobry
Bild des Benutzers dobry
Offline
Zuletzt online: 01.12.2011
Mitglied seit: 31.05.2006
Kommentare: 859
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Man schaue sich mal die Umsätze an, v.a. beim Einbruch vor 1 Monat

_________________

Ich hole sie mir zurück, dieses verdammte Biest!

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Ich finde dein Chart sehr interessant dobry, hohes Volumen auch seit Kurssturzt, decken sich da Profis ein :?: :!:

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

geht aber mächtig bergab...............

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

sascha77 wrote:

geht aber mächtig bergab...............

OK, Italien ist Fussballweltmeister. Immune wird dieses Jahr

Performance Weltmeister!!! basta Biggrin

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Hans wrote:

sascha77 wrote:
geht aber mächtig bergab...............

OK, Italien ist Fussballweltmeister. Immune wird dieses Jahr

Performance Weltmeister!!! basta Biggrin

Weltmeister ja, aber in negativ Performance Blum 3

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
Kursziel $0.09...

IncreMental Advantage Initiates Coverage of The Immune Response Corporation with Price Target of $0.09 Per Share, Accumulate Rating

http://biz.yahoo.com/bw/060724/20060724005555.html?.v=1

..ist zwar eher fraglich, wenn die warrants zu $0.02 ausgeben :roll:

http://biz.yahoo.com/e/060719/imnr.ob8-k.html

..zudem haben die noch NIE ein Medikament auf den Markt gebracht und haben keine einzige Allianz mit einer Pharmafirma vorzuweisen...da ist eher was faul Wink

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

danke für's Update Smile

0.09$ wäre fast das 5fache von meinem EP :mrgreen:

Habe aber nur kleine Portion Venture Capital platziert

schau mer mal, gell Wink

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
....to add approximately $100 million of phantom income...

The Immune Response Corporation Announces It Must Restate First-Quarter 2006 Financial Statements to Add Phantom Income

The Immune Response Corporation (OTCBB:IMNR) announced today that it will restate its first quarter financial statements to add approximately $100 million of phantom income, which has nothing to do with the Company\'s operations. Also, there will be additional phantom income of similar magnitude in the second quarter of 2006. These items do not reflect any change in the Company\'s results of operations or cash position, but are required under a recent clarification of Generally Accepted Accounting Principles.

The restatement relates to a requirement to reflect in first-quarter income a fair market value adjustment for common shares underlying the warrants issued in the Company\'s 2006 private placement. The requirement arose because, when it issued those warrants, the Company did not have enough authorized common stock to honor exercises of the warrants. In determining the adjustment, the Company was required to estimate the fair market value of the Company\'s common stock on March 7, 2006, when most of the private placement securities were issued. On March 7, the closing market price of Company common stock was $0.24. The market, however, did not possess the information that the Company was issuing these many warrants (exercisable at $0.02 per share) and notes (convertible at $0.02 per share). When this information was publicly disclosed, the market price naturally fell; on March 8 and 9, the two days of trading after the public disclosure, the average closing price was $0.13.

The Company believed, and still believes, that if the market had known this information on March 7, the March 7 closing price would have been approximately $0.13, and that therefore the "true" fair market value on March 7 was $0.13 per share. The Company used the $0.13 figure in preparing its first-quarter financial statements and reported, under a GAAP rule known as EITF No. 2000-19, a phantom gain of $12,300,000.

Under the new clarification, using the $0.24 figure is mandatory. Accordingly, the Company will restate its first quarter financial statements to show a phantom EITF No. 2000-19 gain of approximately $115 million rather than of $12.3 million.

On April 11, 2006, the Company increased its authorized number of shares of common stock to 3,500,000,000 and is now able to cover all warrant exercises.

Under a different aspect of EITF No. 2000-19, the Company will be required to report an additional phantom gain of approximately $111 million in its second-quarter financial statements. Under the terms of a registration rights agreement the Company entered into as part of the 2006 private placement, if the Company defaulted under the agreement it might be required to pay damages in the form of stock - more stock, theoretically, than the Company\'s charter authorizes it to issue - if the investor chose to receive damages in the form of stock. This, together with the decline in the Company\'s stock value over the course of the second quarter, requires the additional phantom gain to be posted. Nonetheless, the Company is not in default under the registration rights agreement and does not anticipate any such default.

Immune Response CFO Michael Green said, "These are extreme examples of how GAAP sometimes fails to reflect companies\' financial realities. We had wanted to apply EITF No. 2000-19 pragmatically to avoid showing such a strange amount of truly phantom income in the first quarter; that can only tend to confuse investors. However, the SEC has clarified that GAAP requires us to do exactly that, and so we will issue a restatement."

Mr. Green continued, "We emphasize to investors that there is no economic substance behind either the $115 million first-quarter phantom gain or the $111 million phantom gain which we will report for the 2006 second quarter. We are a development-stage immuno-pharmaceutical company and our operations have never been profitable. Rational investors should pay no heed to the phantom gains, and should evaluate our Company only on its true scientific and business merits."

The filing of the Company\'s second-quarter Form 10-Q will be delayed by a few days to enable it to be redrafted to reflect this matter and to enable the related amended first-quarter Form 10-Q to be prepared.

About The Immune Response Corporation

The Immune Response Corporation (OTCBB:IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company\'s lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.

NeuroVax(TM), which is based on the Company\'s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of multiple sclerosis (MS). NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn\'s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.

IR103 is based on the Company\'s patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of REMUNE(R), the Company\'s first generation HIV product candidate. IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.

NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time. Please visit The Immune Response Corporation at www.imnr.com.

This news release contains forward-looking statements. Forward-looking statements are often signaled by forms of words such as should, could, will, might, plan, projection, forecast, expect, guidance, potential and developing. Actual results could vary materially from those expected due to a variety of risk factors, including whether the Company will continue as a going concern and successfully raise proceeds from financing activities sufficient to fund operations and additional clinical trials of NeuroVax(TM) or IR103, the uncertainty of successful completion of any such clinical trials, the fact that the Company has not succeeded in commercializing any drug, the risk that NeuroVax(TM) or IR103 might not prove to be effective as either a therapeutic or preventive vaccine, whether future trials will be conducted and whether the results of such trials will coincide with the results of NeuroVax(TM) or IR103 in preclinical trials and/or earlier clinical trials. A more extensive set of risks is set forth in The Immune Response Corporation\'s SEC filings including, but not limited to, its Annual Report on Form 10-K for the year ended December 31, 2005, and its subsequent Quarterly Reports filed on Form 10-Q. The Company undertakes no obligation to update the results of these forward-looking statements to reflect events or circumstances after today or to reflect the occurrence of unanticipated events.

REMUNE(R) is a registered trademark of The Immune Response Corporation. NeuroVax(TM) is a trademark of The Immune Response Corporation.

The Immune Response Corporation

Michael K. Green, 760-431-7080

info@imnr.com

Source: Business Wire (August 15, 2006 - 7:02 AM EDT)

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

also ganz alles hab ich nicht verstanden, aber das was ich verstanden habe klingt nicht gut..... :shock:

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Checkt mal das Internet über den Stand der Arbeiten...finde selber nix Smile

Immune Response: Positive HIV-Studie

Datum 19.04.2005 - Uhrzeit 22:11 (©GodmodeTrader - www . godmode-trader.de/)

Immune Response Corp. meldet am Dienstag positive Testergebnisse aus einer Studie mit Mäusen. Ein Antigen des Unternehmens habe sich bei Mäusen als effektiv bei der Verhinderung einer HIV-Infektion erwiesen. Die Ergebnisse der Studie seien im Fachjournal „FASEB“ online veröffentlicht worden. Das genannte Antigen sei das selbe, welches auch in dem firmeneigenen Produkt Remune enthalten sei, hieß es.

****************************************

http://www.pharmaceutical-business-review.com/article_news.asp?guid=1068...

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Hab zwar keine neuen News, aber alle die in medizinischen Titel investiert sind könnte dieser Link interessant sein. Es sind im Archiv auch headlines zu IMNRzu finden:

http://www.medicalnewstoday.com/

Jeden Tag die TOP-News :!: Sehr ausführlich Biggrin

Gruess

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
News

Hoffentlich taugt der etwas........

The Immune Response Corporation Announces Addition of James L. Foght, Ph.D., to Board of Directors

CARLSBAD, Calif.--(BUSINESS WIRE)--Sept. 15, 2006--

The Immune Response Corporation (OTCBB:IMNR), an immuno-pharmaceutical company developing products to treat autoimmune and infectious diseases, announced today that James L. Foght, Ph.D., has joined the company's Board of Directors. Dr. Foght is Managing Partner of Foght Enterprises, L.L.C., which is focused on international business advisory services. He is also Managing Director and a member of the investment committee of Vector Later-Stage Equity Funds, specializing in investments in the life sciences.

"We are pleased to welcome Dr. Foght as a member of the board. His scientific background along with his financial expertise will be an important addition to our board as we advance the clinical programs of IRC's two lead immune-based therapies: NeuroVax(TM) for multiple sclerosis (MS) and IR103 for HIV/AIDS," said Dr. Joseph O'Neill, President and Chief Executive Officer of The Immune Response Corporation.

This February, The Immune Response Corporation announced a new corporate and clinical strategy designed to position the company for long-term success by accelerating the development of its most promising immune-based therapies. Since then, significant progress has been made against this new trajectory by raising substantial capital, presenting promising clinical data for both the MS and HIV products, and demonstrating dramatic yield improvements by their manufacturing facility. Completion of the first stage of enrollment of the IR103 Phase II clinical trials was announced in June and the company is poised to launch its Phase IIb trial for NeuroVax(TM) this fall.

"I am looking forward to working with the impressive management and scientific teams at The Immune Response Corporation," said Dr. Foght. "The company is investigating treatments in HIV and MS, two devastating diseases with significant unmet medical needs."

Dr. Foght was formerly a Managing Director in the Investment Banking division of Prudential Vector Healthcare Group, a unit of Prudential Securities Incorporated. He joined Prudential in July 1999 with the acquisition of Vector Securities International, Inc., which he co-founded in 1988.

Previously, Dr. Foght was Senior Vice President and Co-head of Kidder Peabody's Life Sciences/Medical Products Specialty Group. Prior to that, Dr. Foght spent 23 years with E.I. du Pont de Nemours & Co., spending half of his career in research and research management. He became Managing Director of du Pont U.K. in 1979, with responsibility for 4,000 employees and revenues of $700 million annually. In 1981, Dr. Foght was responsible for the planning and implementation of a de novo pharmaceutical business for du Pont in Europe, Africa, and the Middle East. His responsibilities included managing clinical research, regulatory affairs, licensing, manufacturing, and sales and distribution from headquarters in Frankfurt, Germany. Later, Dr. Foght established a worldwide Technology Evaluation and Acquisition Group for du Pont in the life sciences area.

Dr. Foght earned his M.S. and Ph.D. in organic chemistry with minors in biochemistry and microbiology from the University of Illinois and holds a B.S. from the University of Akron.

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

..demnext Explosionne der Aktie Biggrin

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Hans wrote:

..demnext Explosionne der Aktie Biggrin

Hoi Hans

wie kommst du darauf? Bauchgefühl, eine Meldung, Insider Tip?

Gruess Säschu

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

elmar wrote:

Hallo Hans gebe mir mal die Valora No und Börse danke elmar

Antworte mal Stellvertretend, der Hans nimmst wir hoffentlich nicht über, er ist ganz ok. Wink

Börsen:

- DE Frankfurt und Xetra

- USA Nasdaq OTBB (IMNR)

- Valor: 1500942

Gruess

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

..vorerst noch Geplänkel unter $0.02, dort ist der Deckel drauf, aber der wird wohl irgendwann weggesprengt, dann knallt^s ... ich habe Zeit Smile

Gruss Hans

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

http://biz.yahoo.com/prnews/061026/lath125.html?.v

Spelman Research Initiates Coverage of The Immune Response Corporation With Price Target of $0.059 Per Share

Thursday October 26, 4:28 pm ET

- Research Firm Places Speculative Buy Rating -

CARLSBAD, Calif., Oct. 26 /PRNewswire-FirstCall/ -- The Immune Response Corporation (OTC Bulletin Board: IMNR - News) announced today that Spelman Research, an equity research firm, has initiated coverage on the Company with a price target of $0.059 per share, and a Speculative Buy rating. The Immune Response Corporation's product pipeline has two clinical stage therapeutics in Phase II development, NeuroVax(TM) for multiple sclerosis (MS), and IR103 for HIV/AIDS. The report was issued by Spelman Research's Stelian Mitu, an experienced investment research analyst, who received his CFA charter in 2003 and MBA degree in 1997.

ADVERTISEMENT

In the Spelman report, Mr. Mitu writes, "The drug candidates -- IR103 (HIV) and NeuroVax(TM) (MS) -- are based on innovative technologies that do not have analogues on the market ... If successful, IMNR's drugs may offer significant advantages over their competitors. Unlike existing therapies for treating MS and HIV, which often have very strict administration regimes, are highly toxic, have multiple side effects. IMNR's solutions have so far proven to be safe, cause virtually no side effects and need only be administered on a monthly or quarterly basis, which makes a big difference against some existing therapies whereby patients have to take several pills daily."

To Access the Spelman Research report on The Immune Response Corp

The Spelman Research report on The Immune Response Corporation is available at: www.roiny.com/clients-irc-research.php?f=IMNR-Spelman-Research-Report.pdf

For additional information, please email ROI Group Associates at imnr@roiny.com or call Robert Giordano at 212-495-0201.

Gruss Hans

Trade_Around_Th...
Bild des Benutzers Trade_Around_The_World
Offline
Zuletzt online: 16.04.2012
Mitglied seit: 08.11.2006
Kommentare: 488
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Erste richtige NEWS seit Monaten

SmallCap Sentinel: The Biotech Road of Rags to Riches

IRVINE, Calif., Nov. 9, 2006 (PRIMEZONE) -- An investor-oriented analysis of Immune Response Corp. (OTCBB:IMNR) is now available at SmallCapNetwork.net. The report reveals the potential opportunity found in identifying low-priced biotech stocks based on technology and timing.

The report also highlights the rewarding returns experienced by investors of Amgen, Inc. (Nasdaq:AMGN) and Teva Pharmaceutical (Nasdaq:TEVA) during their early stages of corporate development.

To view the report in its entirety, please visit: http://www.smallcapdigest.net/archive/listserv/20061108-1.html

Access to the information is free of charge. Investors in this sector or small caps in general are invited and encouraged to register for Future briefings and analysis on emergent small and micro cap companies by signing-up at the SmallCap Network\\'s member page: http://www.smallcapnetwork.net/opt.php

About SmallCap Network:

The SmallCap Network, a leading financial publisher, provides equity trading ideas and market guidance through its website http://www.smallcapnetwork.net and free email newsletter, the SmallCap Digest.

The e-newsletter and site focuses on potential up-and-coming small and micro-cap stocks. The SmallCap Network follows the progress of potentially undervalued companies, which may have not yet attracted a major Wall Street following. Third-party research has shown that over time smaller companies, like the ones highlighted by the Small Network, tend to outperform large-cap stocks often featured by most other major media outlets.

The SmallCap Network issues bullish/bearish market calls, and specific stock and option trades, in addition to its profiled companies. The site\\'s trading ideas and guidance have provided outstanding results for readers since inception in 2001. The SmallCap Network also features unique educational content, timely market-related articles and an interactive blog.

Learn more about the SmallCap Network by visiting: http://www.smallcapnetwork.net.

So ist das Leben - mal verliert man,

mal gewinnen die Anderen.

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Kurs aktuell: $0.0192....bis $70 ist ein weiter Weg Wink

http://www.smallcapnetwork.net/archive/listserv/20061108-1.html Smile

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

dann bin ich Multi-Millionär Lol

schon etwas krass, halte aber mein KZ von 0.2$ für realistisch, sollte eines der Medikamente "proven" erreichen und in die Serie gehen, dann wird die Aktie sicher explodieren und unter Umständen das 50 Fache Wert sein.

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

SmileSmileSmile

IMNR hat schon Investoren für Phase III:

Forming Partnerships is One Key to Stock Value

The Immune Response Corporation (OTCBB: IMNR)

IMNR has a corporate strategy which involves three steps to achieve success:

Within the coming two years to:

* Complete Phase II for MS and HIV;

* Form private and public partnerships;

* Initiate clinical development of second autoimmune product for Psoriasis

Successful Phase II Clinical Trial completion should signal strong interest in IMNR. It will be important to keep a close eye on IMNR as they approach this pivotal milestone for not one but two incredibly important drugs which will treat two massive diseases: MS and HIV.

The IR103 development plan (link here for time line) includes the following steps:

* Forming public and private partnerships to support Phase III and commercialization. IMNR also is planning to get involved in the HIV prevention area and has already applied for its first government contract and is planning further efforts to seek international government and NGO funding.

* Benefiting from substantial public resources for HIV treatment offered by Government Agencies, UNAIDS, WHO.

The time line chart indicates that final results for IR103 will be reported in the third quarter of 2007 with trials beginning in January of 2007.

Source:

Immune Response Corp. (The)

Gruss Hans

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

That sounds wonderful Biggrin

Dann sehen wir bald höhere Kurse, so im 2007 müste das Ding explodieren, da die Börse die künftige Entwicklung von IMNR vorweggnehmen wird.

Trade_Around_Th...
Bild des Benutzers Trade_Around_The_World
Offline
Zuletzt online: 16.04.2012
Mitglied seit: 08.11.2006
Kommentare: 488
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Gerade vorher sind 300'000 Aktien zu 0.03 über den Ladentisch bei der Xetra. +150%

So ist das Leben - mal verliert man,

mal gewinnen die Anderen.

Trade_Around_Th...
Bild des Benutzers Trade_Around_The_World
Offline
Zuletzt online: 16.04.2012
Mitglied seit: 08.11.2006
Kommentare: 488
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Sorry es war 0.025 pro Aktie. Lol

So ist das Leben - mal verliert man,

mal gewinnen die Anderen.

brasilhardy
Bild des Benutzers brasilhardy
Offline
Zuletzt online: 20.06.2007
Mitglied seit: 08.11.2006
Kommentare: 31
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

der Kurs scheint eher zu sinken, Aktuell -4,33% Aktie bei 0,0198

sascha77
Bild des Benutzers sascha77
Offline
Zuletzt online: 10.09.2012
Mitglied seit: 19.05.2006
Kommentare: 543
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Trade_Around_The_World wrote:

Sorry es war 0.025 pro Aktie. Lol

die Xetra handelt leider nur 1 Mal pro Tag mit IMNR. Da ist der Kurs an der FRA Börse vom Traden her viel dynamischer. Habe aber meine auch bei Xetra eingekauft, da ich (noch)mit Yellowtrade handle.

Ist schon "crazy" was da heute abging mit den 300'000Stk. = ca. 12'000.-

brasilhardy
Bild des Benutzers brasilhardy
Offline
Zuletzt online: 20.06.2007
Mitglied seit: 08.11.2006
Kommentare: 31
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Wenn ich unter Tradejet IMNR eingebe, dann zeigt er mir an, dass der Titel nur an der Nasdaq getraded wird.

Kann mir jemand einen anderen Link angeben von anderen Börsenplätzen wo der Titel auch gehandelt wird?

Trade_Around_Th...
Bild des Benutzers Trade_Around_The_World
Offline
Zuletzt online: 16.04.2012
Mitglied seit: 08.11.2006
Kommentare: 488
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

@Brasilhardy

Klick mal den Link an:

http://www.cash.ch/search/kurse/aktien/immune%20response

@Sascha77

Manchmal ist es ein Vorteil und manchmal ein Nachteil das nur einmal am Tag gehandelt wird.Man hat immer bis etwa 14Uhr Zeit um seine Limite zu setzen.Je nach Kursverlauf.

Was micht stört ist das Geld und Brief nie richtig angezeigt werden.

Ist das bei dir auch so?

Zu welchem EP bist du dabei wenn ich fragen darf?

So ist das Leben - mal verliert man,

mal gewinnen die Anderen.

Hans
Bild des Benutzers Hans
Offline
Zuletzt online: 17.08.2017
Mitglied seit: 22.05.2006
Kommentare: 2'003
ORCHESTRA THERAP. (OCHT.OB) mit 3 Medis in Phase 2....

Cash-Kurs bei OTSs ist echt Schrott Biggrin

Probiers hier:

http://www.investorshub.com/boards/quotes.asp?ticker=IMNR&qm_page=30649&...

...mit Depth/LII sieht man dort auch noch was aktuell geschüttet wird Wink

Gruss Hans

Seiten